natgillin/translations-raw huggingface dataset:
The oral dosage form of claim 14 or 15 wherein the subject is a human and the human is being treated with an agent that causes potassium retention, the agent that causes potassium retention being an angiotensin-converting enzyme inhibitor (optionally captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, fosinopril, or a combination thereof), an angiotensin receptor blocker (optionally candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, or a combination thereof), or an aldosterone antagonist (optionally spironolactone, eplerenone, or a combination thereof). 
Farmaceutski pripravak prema bilo kojem od zahtjeva 12 do 14 naznačen time da subjekt je čovjek i čovjek se liječi sa sredstvom koje uzrokuje zadržavanje kalija, te sredstvo koje uzrokuje zadržavanje kalija je inhibitor angiotenzin-konvertirajućeg enzima (proizvoljno kaptopril, zofenopril, enalapril, ramipril, kinapril, perindopril, lizinopril, benazipril, fosinopril, ili njihova kombinacija), blokator receptora angiotenzina (proizvoljno kandesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, ili njihova kombinacija), antagonist aldosterona (proizvoljno spironolakton, eplerenon, ili njihova kombinacija).
A medicament delivery device, comprising: 
Uređaj za isporuku lijeka koji sadrži:
The liposome according to any one of the preceding claims, characterized in that the said liposome further comprises a charged phospholipid, wherein the said charged phospholipid is selected from the group consisting of dilauroyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol, distearoyl phosphatidyl glycerol, dimyristate phosphatidylglycerol, dioleic acid phosphatidylserine, dioleoyl phosphatidylglycerol, dilauroyl phosphatidic acid, dimyristate phosphatidic acid, distearoyl phosphatidic acid and a mixture thereof, and the weight ratio of the charged phospholipid to the neutral phospholipid is 1:5 ∼ 1:100. 
Liposom prema bilo kojem od prethodnih zahtjeva, naznačen time što taj liposom dalje sadrži nabijeni fosfolipid, pri čemu se taj nabijeni fosfolipid izabire iz skupine koja obuhvaća dilauroil fosfatidilglicerol, dipalmitoil fosfatidilglicerol, distearoil fosfatidil glicerol, dimiristat fosfatidilglicerol, fosfatidilserin dioleinske kiseline, dioleoil fosfatidilglicerol, dilauroil fosfatidinske kiseline, dimiristat fosfatidinske kiseline, distearoil fosfatidinske kiseline i njihove mješavine, i težinski omjer nabijenog fosfolipida prema neutralnom fosfolipidu je 1: 5 ~ 1: 100.
dissolving a neutral phospholipid and cholesterol into anhydrous ethanol or a mixed solvent of anhydrous ethanol and tert-butyl alcohol according to the desired formulation, mixing the mixture with a buffer to obtain a crude blank liposome after removing ethanol through reduced pressure distillation, and then preparing a blank liposome with the desired particle size by using high-pressure homogenizer and/or extrusion equipment; 
otapanje neutralnog fosfolipida i kolesterola u bezvodnom etanolu ili miješanom otapalu bezvodnog etanola i tert-butil alkohola ovisno o željenoj formulaciji, miješanje smjese s puferom da se dobije sirovi prazni liposom nakon uklanjanja etanola putem destilacije pod sniženim tlakom, i zatim priprema praznog liposoma sa željenom veličinom čestica uporabom opreme homogenizatora s visokim pritiskom i/ili za ekstruziju;
dissolving a neutral phospholipid and cholesterol into chloroform or a chloroform-methanol mixed solvent according to the desired formulation, forming a lipid film through rotary evaporator, adding a buffer for hydration to obtain a crude blank liposome, and then preparing a blank liposome with the desired particle size by using high pressure homogenizer and/or extrusion equipment; 
otapanje neutralnog fosfolipida i kolesterola u kloroformu ili miješanom otapalu kloroform-metanol ovisno o željenoj formulaciji, formiranje lipidnog filma rotacijskim evaporatorom, dodavanje pufera za hidriranje da se dobije sirovi prazni liposom, i zatim priprema praznog liposoma sa željenom veličinom čestica uporabom opreme homogenizatora s visokim pritiskom i/ili za ekstruziju;
dissolving a neutral phospholipid and cholesterol into anhydrous ethanol or a mixed solvent of anhydrous methanol and tert-butyl alcohol according to the desired formulation, mixing the mixture with a buffer, and then preparing a blank liposome with the desired particle size by using high pressure homogenizer and/or extrusion equipment; 
otapanje neutralnog fosfolipida i kolesterola u bezvodnom etanolu ili miješanom otapalu bezvodnog etanola i tert-butil alkohola ovisno o željenoj formulaciji, miješanje smjese s puferom, i zatim priprema praznog liposoma sa željenom veličinom čestica uporabom opreme homogenizatora s visokim pritiskom i/ili za ekstruziju;
preparation of a drug-loaded liposome: preparing an aqueous solution of irinotecan hydrochloride, adding it to the dispersion of blank liposome with ionic gradient, and then incubating the dispersion to obtain the drug-loaded liposome under heating and stirring. 
priprema liposoma napunjenog lijekom: priprema vodene otopine irinotekan hidroklorida, njezino dodavanje u disperziju praznog liposoma s gradijentom iona, i zatim inkubacija disperzije da se dobije liposom napunjen lijekom uz zagrijavanje i miješanje.
removal of the free drug and concentration of the sample: adding a buffer medium to irinotecan hydrochloride liposome, removing the non-encapsulated drug by using tangential flow device, and concentrating the sample to appropriate volume. 
uklanjanje slobodnog lijeka i koncentriranje uzorka: dodavanje puferskog medija u liposom irinotekan hidroklorida, ukanjanje ne-ovijenog lijeka uporabom uređaja tangencijalnog toka, i koncentriranje uzorka do odgovarajućeg volumena.
The liposome injection according to claim 15, characterized in that the said injection comprises a stabilizer, wherein the said stabilizer is selected from the group consisting of ethylene diamine tetraacetic acid, ethylene diamine tetraacetic acid disodium, ethylene diamine tetraacetic acid dicalcium and a mixture thereof preferably ethylene diamine tetraacetic acid disodium; the ratio of the stabilizer added is 0 ∼ 0.5% (w/v), and the minimum is not 0%. 
Injekcija liposoma prema zahtjevu 13, naznačena time što ta injekcija sadrži stabilizator, pri čemu se taj stabilizator izabire iz skupine koja obuhvaća etilen diamin tetraoctenu kiselinu, dinatrij etilen diamin tetraoctene kiseline, dikalcij etilen diamin tetraoctene kiseline i njihove smjese, poželjno dinatrij etilen diamin tetraoctene kiseline; omjer dodanog stabilizatora je 0 ~ 0,5% (tež/vol), i minimum nije 0%.
The liposome injection according to claim 13, characterized in that the said injection is liquid injection or lyophilized powder for injection. 
Injekcija liposoma prema zahtjevu 13, naznačena time što je ta injekcija tekuća injekcija ili liofilizirani prašak za injekciju.
The liposome injection according to claim 15, characterized in that the said injection further comprises an antioxidant, wherein the said antioxidant is selected from the group consisting of a water-soluble antioxidant and an oil-soluble antioxidant: wherein the said oil-soluble antioxidant is selected from the group consisting of a-tocopherol, a-tocopherol succinate, a-tocopherol acetate and a mixture thereof: wherein the said water-soluble antioxidant is selected from the group consisting of ascorbic acid, sodium bisulfite, sodium sulfite, sodium pyrosulfite. L-cysteine and a mixture thereof: the ratio of the antioxidant added is 0 ∼ 0.5% (w/v), and the minimum is not 0%. 
Injekcija liposoma prema zahtjevu 13, naznačena time što ta injekcija dalje sadrži antioksidans, pri čemu se taj antioksidans izabire iz skupine koja obuhvaća u vodi topljiv antioksidans i u ulju topljiv antioksidans; gdje se taj u ulju topljiv antioksidans izabire iz skupine koja obuhvaća a-tokoferol, a-tokoferol sukcinat, a-tokoferol acetat i njihove smjese; gdje se taj u vodi topljiv antioksidans izabire iz skupine koja obuhvaća askorbinsku kiselinu, natrijev bisulfit, natrijev sulfit, natrijev pirosulfit, L-cistein i njihove smjese; omjer dodanog antioksidansa je 0 ~ 0,5% (tež/vol), i minimum nije 0%.
The liposome injection according to claim 15. characterized in that the said injection is lyophilized powder for injection which comprises a lyoprotectant, and is prepared by freeze-drying. 
Injekcija liposoma prema zahtjevu 15, naznačena time što je ta injekcija liofilizirani prašak za injekciju koji sadrži lioprotektant i priprema se sušenjem putem zamrzavanja.
the method comprising administering the compound in combination with gemcitabine or a taxoid. 
pri čemu postupak obuhvaća primjenu spoja u kombinaciji s gemcitabinom ili taksoidom.
The compound for use in a method for the treatment of cancer according to claim 1, wherein the compound is 5-(2-fluoro-4-iodophenylamino)-imidazo[1,5-a]pyridine-6-carboxylic acid (2-hydroxyethoxy)-amide, or a pharmaceutically acceptable salt thereof. 
Spoj za uporabu u postupku liječenja raka prema zahtjevu 1, naznačen time, da spoj je -(2-fluoro-4-jodofenilamino)-imidazo[1,5-a]piridin-6-karboksilna kiselina-(2-hidroksietoksi)-amid, ili njegova farmaceutski prihvatljiva sol.
The compound for use in a method for the treatment of cancer according to claim 1 or claim 2, wherein the cancer is pancreatic cancer, non-small cell lung cancer, colorectal cancer, endometrial cancer, ovarian cancer or melanoma. 
Spoj za uporabu u postupku liječenja raka prema zahtjevu 1 ili zahtjevu 2, naznačen time, da rak je rak gušterače, rak nemalih stanica pluća, kolorektalni rak, endometrijski rak, rak jajnika ili maligni melanom.
The compound for use in a method for the treatment of cancer according to one one of claims 1 to 3, wherein the compound is administered sequentially to the taxoid or gemcitabine. 
Spoj za uporabu u postupku liječenja raka prema bilo kojem od zahtjeva 1 do 3, naznačen time, da se spoj primjenjuje uzastopno nakon taksoida ili gemcitabina.
A compound for use in a method for the treatment of a condition characterised by mutation or overexpression of MEK kinase, wherein the compound is selected from: 
Spoj, naznačen time, da se upotrebljava u postupku liječenja raka ili upalnog poremećaja, kojemu je svojstvena mutacija ili prekomjerna ekspresija MEK-kinaze, pri čemu je spoj odabran od sljedećih:
A method of decoding a video image, the method comprising: 
Postupak dekodiranja video slike, naznačen time da postupak obuhvaća:
an emergency release coupling (ERC) (500) mechanically coupled to the conduit (52); 
spojku za odspajanje u slučaju nužde (ERC) (500) mehanički spojenu na vod (52);
The apparatus of claim 1, wherein the radio receiver (502) further comprises an antenna (506). 
Uređaj prema zahtjevu 1, naznačen time da radio prijemnik (502) dodatno sadrži antenu (506).
sending a radio signal to the ERC (500) when the measured movement unacceptably deviates from at least one preset parameter; and pneumatically actuating the ERC upon receipt of the radio signal, wherein actuating the ERC decouples the conduit. 
slanje radio signala prema ERC (500) kada izmjerena udaljenost odstupa od najmanje jednog unaprijed postavljenog parametra; i pneumatsko aktiviranje ERC (500) nakon prijema radio signala, pri čemu aktiviranje ERC (500) odspaja vod (52).
The method of claim 8, wherein the radio signal is initiated by the computer (82) or the PLC. 
Postupak prema zahtjevu 8, naznačen time da je radio signal iniciran od strane računala (82), pri čemu računalo (82) obrađuje podatke primljene od prvog i drugog transpondera (80).
The method of claim 8, wherein sending the radio signal occurs when the measured movement unacceptably deviates from the at least one preset parameter for a preset duration of time. 
Postupak prema zahtjevu 8, naznačen time da se slanje radio signala odvija kada izmjerena udaljenost odstupa od najmanje jednog unaprijed postavljenog parametra tijekom unaprijed postavljenog vremenskog perioda.
Composite material comprising: a plastics matrix and a filler, characterized in that 
Kompozitni materijal koji sadrži: plastičnu matricu i punjenje, naznačen time što:
the plastic material is PET waste. 
Plastični materijal je PET otpad.
Composite material according to claim 1 wherein the grinded asbestos-cement has the particle size between 2-5 micrometers. 
Kompozitni materijal sukladno Zahtjevu 1 pri čemu mljeveni azbestni cement sadrži čestice veličine između 2 - 5 mikrometara.
Composite material according to any one of the claims 1-3 wherein the ratio of grinded asbestos-cement is of 20% by weight. 
Kompozitni materijal sukladno bilo kojem od Zahtjeva 1-2 pri čemu je udio mljevenog azbestnog cementa 20 % težine.
Composite material according to any of claims 1-4, that comprises also alumina Al2O3. 
Kompozitni materijal sukladno bilo kojem od Zahtjeva 1- 4, koji također sadrži aluminijev oksid AL₂O₃.
Use of PET plastic material to neutralize asbestos-cement or asbestos-cement waste. 
Uporaba PET plastičnog materijala radi neutralizacije azbestnog cementa ili otpada azbestnog cementa.
Method for recycling of asbestos-cement or asbestos-cement waste consisting of embedding the asbestos-cement in a plastics matrix made of a plastic material which is PET. 
Postupak recikliranja azbestnog cementa ili otpada azbestnog cementa koji se sastoji od smještanja azbestnog cementa ili otpada azbestnog cementa u plastično kućište načinjeno od plastičnog materijala koji je PET.
Use of a compound according to claims 1-9 for the production of a medicament for prevention and/or treatment of Systemic Sclerosis (SSc) comprising an effective amount of a compound according to claims 1 to 9. 
Uporaba spoja prema zahtjevima 1-9 naznačena time da je za proizvodnju lijeka za prevenciju i/ili liječenje sistemske skleroze (SSc) koji sadrži učinkovitu količinu spoja prema zahtjevima 1 do 9.
Use of a compound according to claims 1-9 for the production of a medicament for prevention and/or treatment of Systemic Systemic Sclerosis (SSc), diffuse Systemic Sclerosis (dSSc), limited Systemic Sclerosis (ISSc), overlap type of Systemic Sclerosis, undifferentiated type of Systemic Sclerosis, Systemic Sclerosis sine scleroderma, skin fibrosis, scleroderma, nephrogenic fibrosing dermopathy (NFD), keloid formation comprising an effective amount of a compound according to claims 1 to 9. 
Uporaba spoja prema zahtjevima 1-9 naznačena time da je za proizvodnju lijeka za prevenciju i/ili liječenje sistemske skleroze (SSc), difuzne sistemske skleroze (dSSc), ograničene sistemske skleroze (lSSc), preklapajućeg tipa sistemske skleroze, nediferenciranog tipa sistemske skleroze, sistemske skleroze bez sklerodermije, fibroze kože, sklerodermije, nefrogene fibrozne dermopatije (NFD), stvaranja keloida, koji sadrži učinkovitu količinu spoja prema zahtjevima 1 do 9.
Use of a compound according to claims 1-9 for the production of a medicament for prevention and/or treatment of Systemic Sclerosis SSc concomitant fibrosis of internal organs, comprising the guts, the lungs, the kidneys and the blood vessels comprising an effective amount of a compound according to claims 1 to 9. 
Uporaba spoja prema zahtjevima 1-9 naznačena time da je za proizvodnju lijeka za prevenciju i/ili liječenje sistemske skleroze SSc uz popratnu fibrozu unutrašnjih organa, koji obuhvaćaju crijeva, pluća, bubrege i krvne žile koji sadrži učinkovitu količinu spoja prema zahtjevima 1 do 9.
Pharmaceutical formulation comprising at least one compound or one combination according to claims 1 to 9 for the use in the prevention and/or treatment of Systemic Sclerosis (SSc), diffuse Systemic Sclerosis (dSSc), limited Systemic Sclerosis (ISSc), overlap type of Systemic Sclerosis, undifferentiated type of Systemic Sclerosis, Systemic Sclerosis sine scleroderma, skin fibrosis, scleroderma, nephrogenic fibrosing dermopathy (NFD), keloid formation. 
Farmaceutska formulacija koja sadrži barem jedan spoj ili jednu kombinaciju prema zahtjevima 1 do 9 naznačena time da je za uporabu za prevenciju i/ili liječenje sistemske skleroze (SSc), difuzne sistemske skleroze (dSSc), ograničene sistemske skleroze (lSSc), preklapajućeg tipa sistemske skleroze, nediferenciranog tipa sistemske skleroze, sistemske skleroze bez sklerodermije, fibroze kože, sklerodermije, nefrogene fibrozne dermopatije (NFD), stvaranja keloida.
Kit according to claims 16 and 17 for the use in the prevention and/or treatment of Systemic Sclerosis SSc concomitant fibrosis of internal organs, comprising the guts, the lungs, the kidneys and the blood vessels. 
Komplet prema zahtjevima 16 i 17 naznačen time da je za uporabu za prevenciju i/ili liječenje sistemske skleroze SSc uz popratnu fibrozu unutrašnjih organa, koji obuhvaćaju crijeva, pluća, bubrege i krvne žile.
A cylinder lock (1) according to Claim 4, wherein the cylinder lock further comprises an external connection apparatus (16) connected to said connector (14). 
Cilindrična brava (1) prema zahtjevu 4, naznačena time da cilindrična brava nadalje sadrži vanjski konektorski aparat (16) spojen s navedenim konektorom (14).
A cylinder lock (1) according to Claim 4, wherein the cylinder lock further comprises a buzzer box (17) connected to said connector (14). 
Cilindrična brava (1) prema zahtjevu 4, naznačena time da cilindrična brava nadalje sadrži kućište naprave za ispuštanje zvučnog signala (17) spojeno s navedenim konektorom (14).
A cylinder lock (1) according to Claim 1 wherein the volume formed on said first cylinder half (21) is closed with a cover (9). 
Cilindrična brava (1) prema zahtjevu 1, naznačena time da je prostor oblikovan u navedenoj prvoj polovici cilindra (21) zatvoren navlakom (9).
The apparatus of claim 1, wherein the pneumatic release system (504, 508, 510, 512) decouples the conduit (52) from the sending location (10) and/or the receiving location (14). 
Uređaj prema zahtjevu 1, naznačen time da sustav pneumatskog otpuštanja (504, 508, 510, 512) odspaja vod (52) od mjesta slanja (10) i/ili mjesta prihvata (14).
The apparatus of claim 1, further comprising a computer (82), wherein the computer (82) signals the radio receiver (502) to trigger the pneumatic release system (504, 508, 510,512). 
Uređaj prema zahtjevu 1, koji dodatno sadrži računalo (82), naznačen time da računalo (82) signalizira radio prijemniku (502) da aktivira sustav pneumatskog otpuštanja (504, 508, 510,512).
The apparatus as claimed in claim 1, wherein the transponders (80) signal the computer (82) to signal the radio receiver (502) and/or signal an alarm (86). 
Uređaj prema zahtjevu 1, naznačen time da transponderi (80) signaliziraju računalu (82) da signalizira radio prijemniku (502) i/ili da aktivira alarm (86).
sending a radio signal to the ERC (500) when the measured distance deviates from at least one preset parameter; and pneumatically actuating the ERC (500) upon receipt of the radio signal, wherein actuating the ERC (500) decouples the conduit (52). 
slanje radio signala prema ERC (500) kada izmjerena udaljenost odstupa od najmanje jednog unaprijed postavljenog parametra; i pneumatsko aktiviranje ERC (500) nakon prijema radio signala, pri čemu aktiviranje ERC (500) odspaja vod (52).
The method of claim 1, wherein the radio signal is initiated by a computer (82), wherein the computer (82) processes information received from the first and second transponders (80). 
Postupak prema zahtjevu 8, naznačen time da je radio signal iniciran od strane računala (82), pri čemu računalo (82) obrađuje podatke primljene od prvog i drugog transpondera (80).
The method as claimed in claim 8, wherein sending the radio signal occurs when the measured distance deviates from at least one preset parameter for a preset duration of time. 
Postupak prema zahtjevu 8, naznačen time da se slanje radio signala odvija kada izmjerena udaljenost odstupa od najmanje jednog unaprijed postavljenog parametra tijekom unaprijed postavljenog vremenskog perioda.
The method of claim 1, wherein the ERC (500) further comprises an antenna (506) and a receiver (502). 
Postupak prema zahtjevu 8, naznačen time da ERC (500) dodatno sadrži antenu (506) i prijemnik (502).
The method of claim 8, wherein the conduit (52) further comprises a shut down valve (410) and/or a quick release system (340). 
Postupak prema zahtjevu 8, naznačen time da vod (52) dodatno sadrži ventil za isključivanje (410) i/ili sustav za brzo otpuštanje (340).
A shotgun according to any of the previous claims, characterized in that the fastening mechanism is positioned on an underside of the forearm. 
Puška sukladno bilo kojem od prethodnih Zahtjeva, naznačena time što je mehanizam za pričvršćivanje smješten s donje strane rukohvata.
A shotgun according to any of the previous claims, characterized in that the sling mount is on a front end of the forearm. 
Puška sukladno bilo kojem od prethodnih Zahtjeva, naznačena time što je nosač remena na prednjem kraju rukohvata.
A shotgun according to claim 5, characterized in that the fastening mechanism pivots outward from the forearm to move to the first position and to the second position. 
Puška sukladno Zahtjevu 5, naznačena time što mehanizam za pričvršćivanje zakreće prema van u odnosu na rukohvat kako bi se pomaknuo u prvi i drugi položaj.
Element according to claim 4, characterised in that the layer of hot-melt adhesive (7) extends to around two millimetres from the edge (8) concerned of the support (2). 
Element sukladno Zahtjevu 4, naznačen time što se sloj termotopivog ljepila (7) pruža do udaljenosti od otprilike dva milimetra od ruba (8) potpornja (2).
Element according to any one of the claims 3 to 7, characterised in that the element (1) is provided with an adhesive strip (11) of binding adhesive for the subsequent securing of the bundle of leaves (21) in the binding folder (19). 
Element sukladno bilo kojem od Zahtjeva 3 do 7, naznačen time što element (1) dolazi s ljepljivom trakom (11) za naknadno osiguravanje snopa listova (21) u uložnoj mapi (19).
Element according to claim 9, characterised in that the adhesive strip (11) of binding adhesive is formed by a self-adhesive strip that is protected by a removable protective sheet. 
Element sukladno Zahtjevu 9, naznačen time što je ljepljiva traka (11) formirana pomoću samoljepljive trake koja je zaštićena odvojivom zaštitnom folijom.
Element according to any of the previous claims, characterised in that the layer of holt-melt adhesive (7) has a thickness superior to 20 micrometres. 
Element sukladno bilo kojem od prethodnih Zahtjeva, naznačen time što je sloj termotopivog ljepila (7) debljine veće od 20 mikrometara.
Element according to any of the previous claims, characterised in that the layer of holt-melt adhesive (7) has a thickness inferior to 50 micrometres. 
Element sukladno bilo kojem od prethodnih Zahtjeva, naznačen time što je sloj termotopivog ljepila (7) debljine manje od 50 mikrometara.
Method according to claim 16, characterised in that the finished cover (12) is bonded to the support (2) under pressure. 
Postupak sukladno Zahtjevu 16, naznačen time što je završni omot (12) spojen s potpornjem (2) pod pritiskom.
Method according to any one of claims 16 to 18, characterised in that, if there is an adhesive strip (11) of hot-melt adhesive, this adhesive strip (11) is shielded from the heat during the heating process. 
Postupak sukladno bilo kojem od Zahtjeva 16 do 18, naznačen time što, ukoliko postoji ljepljiva traka (11) od termotopivog ljepila, ova ljepljiva traka (11) zaštićena je od vrućine tijekom postupka zagrijavanja.
Method according to claim 16 to manufacture a binding folder with a U-shaped back (17) and two endpapers (20), characterised in that the central strip (3) is deformed into a U-shaped back (17). 
Postupak sukladno Zahtjevu 16 za proizvodnju uložne mape s pozadinom oblika slova U (17) i dva krajnja lista (20), naznačen time što je središnja traka (3) oblikovana u pozadinu oblika slova U (17).
and Y1, together with the atoms to which they are attached, are benzene, naphthylene, heteroarene, cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; and 
i Y1 zajedno s atomima na koje su priključeni, čine benzen, naftalen, heteroaren, cikloalkan, cikloalken, heterocikloalkan ili heterocikloalken; i